Rtw Investments buys $5,638,452 stake in Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX) : Rtw Investments scooped up 274,851 additional shares in Celldex Therapeutics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,264,227 shares of Celldex Therapeutics which is valued at $5,638,452.Celldex Therapeutics makes up approximately 1.72% of Rtw Investments’s portfolio.

Other Hedge Funds, Including , Squarepoint Ops added CLDX to its portfolio by purchasing 77,400 company shares during the most recent quarter which is valued at $345,204. Celldex Therapeutics makes up approx 0.03% of Squarepoint Ops’s portfolio. Tfs Capital sold out all of its stake in CLDX during the most recent quarter. The investment firm sold 11,840 shares of CLDX which is valued $52,806.Martingale Asset Management L P reduced its stake in CLDX by selling 6 shares or 0.02% in the most recent quarter. The Hedge Fund company now holds 25,362 shares of CLDX which is valued at $113,115.Blackrock Fund Advisors boosted its stake in CLDX in the latest quarter, The investment management firm added 167,033 additional shares and now holds a total of 3,767,356 shares of Celldex Therapeutics which is valued at $16,802,408. Blackrock Japan Ltd sold out all of its stake in CLDX during the most recent quarter. The investment firm sold 238 shares of CLDX which is valued $1,061.

Celldex Therapeutics opened for trading at $3.53 and hit $3.69 on the upside on Wednesday, eventually ending the session at $3.66, with a gain of 3.68% or 0.13 points. The heightened volatility saw the trading volume jump to 1,808,168 shares. Company has a market cap of $368 M.

On the company’s financial health, Celldex Therapeutics reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.34. The company had revenue of $1.40 million for the quarter, compared to analysts expectations of $.96 million. The company’s revenue was down -36.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.33 EPS.

Celldex Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development includes varlilumab also referred to as CDX-1127 a fully human therapeutic monoclonal antibody for cancer indications CDX-1401 a targeted immunotherapeutic for cancer indications and CDX-301 an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Leave a Reply

Celldex Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celldex Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.